Salvage Therapy for Relapsed/Refractory Diffuse Large B Cell Lymphoma

Biology of Blood and Marrow Transplantation

Volumn 14, Issue 3, 2008, Pages 259-267

  Seshadri, Tara ^a   Kuruvilla, John ^a   Crump, Michael ^a   Keating, Armand ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Diffuse large B cell lymphoma; Refractory; Relapsed; Salvage therapy

Indexed keywords

BEVACIZUMAB; BIOLOGICAL MARKER; BORTEZOMIB; BUSULFAN; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ENZASTAURIN; ETOPOSIDE; FLUDARABINE; GEMCITABINE; HISTONE DEACETYLASE INHIBITOR; IBRITUMOMAB TIUXETAN; IFOSFAMIDE; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE SODIUM SUCCINATE; NAVELBINE; OXALIPLATIN; PLATINUM COMPLEX; PREDNISOLONE; PREDNISONE; RITUXIMAB; TOSITUMOMAB I 131; UNINDEXED DRUG; VINCRISTINE;

ANEMIA; ANTINEOPLASTIC ACTIVITY; B CELL LYMPHOMA; BLOOD TOXICITY; BONE MARROW TOXICITY; CANCER REGRESSION; CANCER SURVIVAL; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONFUSION; DIARRHEA; DRUG CYTOTOXICITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ERYTHROCYTE TRANSFUSION; FEBRILE NEUTROPENIA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; LARGE CELL LYMPHOMA; MINIMAL RESIDUAL DISEASE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; PERIPHERAL NEUROPATHY; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; RADIOIMMUNOTHERAPY; RECURRENT CANCER; REVIEW; SALVAGE THERAPY; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; UROGENITAL TRACT DISEASE;

FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECURRENCE; SALVAGE THERAPY; TRANSPLANTATION, AUTOLOGOUS; TUMOR MARKERS, BIOLOGICAL;

EID: 38949115531     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2007.11.013     Document Type: Review

References (74)

1. Feugier P., Van Hoof A., Sebban C., et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 23 (2005) 4117-4126
2. Pfreundschuh M.T.L., Osterborg A., Pettengell R., et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7 (2006) 379-391
3. Fisher R.I., Gaynor E.R., Dahlberg S., et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328 (1993) 1002-1006
4. Philip T., Guglielmi C., Hagenbeek A., et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333 (1995) 1540-1545
5. Mills W., Chopra R., McMillan A., et al. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol 13 (1995) 588-595
6. Wheeler C., Strawderman M., Ayash L., et al. Prognostic factors for treatment outcome in autotransplantation of intermediate-grade and high-grade non-Hodgkin's lymphoma with cyclophosphamide, carmustine, and etoposide. J Clin Oncol 11 (1993) 1085-1091
7. Schutt P., Passon J., Ebeling P., et al. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas. Eur J Haematol 78 (2007) 93-101
8. Project-The International Non Hodgkin's Lymphoma Prognostic Factor: a predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 329 (1993) 987-994
9. Blay J.Y., Gomez F., Sebban C., et al. The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Blood 92 (1998) 3562-3568
10. Hamlin P.A., Zelenetz A.D., Kewalramani T., et al. Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood 102 (2003) 1989-1996
11. Guglielmi C., Martelli M., Federico M., et al. Risk-assessment in diffuse large cell lymphoma at first relapse. A study by the Italian Intergroup for Lymphomas. Haematologica 86 (2001) 941-950
12. Rodriguez-Catarino M., Jerkeman M., Ahlström H., et al. Residual mass in aggressive lymphoma-does size, measured by computed tomography, influence clinical outcome?. Acta Oncol 39 (2000) 485-489
13. Seam P., Juweid M.E., and Cheson B.D. The role of FDG-PET scans in patients with lymphoma. Blood 110 (2007) 3507-3516
14. Spaepen K., Stroobants S., Dupont P., et al. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?. J Clin Oncol 19 (2001) 414-419
15. Jerusalem G., Beguin Y., Fassotte M.F., et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 94 (1999) 429-433
16. Schot B., van Imhoff G., Pruim J., et al. Predictive value of early 18F-fluoro-deoxyglucose positron emission tomography in chemosensitive relapsed lymphoma. Br J Haematol 123 (2003) 282-287
17. Filmont J.-E., Czernin J., Yap C., et al. Value of F-18 fluorodeoxyglucose positron emission tomography for predicting the clinical outcome of patients with aggressive lymphoma prior to and after autologous stem-cell transplantation. Chest 124 (2003) 608-613
18. Spaepen K., Stroobants S., Dupont P., et al. Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. Blood 102 (2003) 53-59
19. Schot B.W., Zijlstra J.M., Sluiter W.J., et al. Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma. Blood 109 (2007) 486-491
20. Schot B.W., Pruim J., van Imhoff G.W., et al. The role of serial pre-transplantation positron emission tomography in predicting progressive disease in relapsed lymphoma. Haematologica 91 (2006) 490-495
21. Alizadeh A.A., Eisen M.B., Davis R.E., et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403 (2000) 503-511
22. Hans C.P., Weisenburger D.D., Greiner T.C., et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103 (2004) 275-282
23. De Paepe P., and De Wolf-Peeters C. Diffuse large B-cell lymphoma: a heterogeneous group of non-Hodgkin lymphomas comprising several distinct clinicopathological entities. Leukemia 21 (2007) 37-43
24. Shipp M.A., Ross K.N., Tamayo P., et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 8 (2002) 68-74
25. Moskowitz C.H. Pretreatment prognostic factors and outcome in patients with relapsed or primary-refractory diffuse large B-cell lymphoma treated with second-line chemotherapy and autologous stem cell transplantation. Ann Oncol 17 (2006) iv37-iv39
26. Moskowitz C.H., Zelenetz A.D., Kewalramani T., et al. Cell of origin, germinal center versus nongerminal center, determined by immunohistochemistry on tissue microarray, does not correlate with outcome in patients with relapsed and refractory DLBCL. Blood 106 (2005) 3383-3385
27. Haarer C.F., Roberts R.A., Frutiger Y.M., et al. Immunohistochemical classification of de novo, transformed, and relapsed diffuse large B-cell lymphoma into germinal center B-cell and nongerminal center B-cell subtypes correlates with gene expression profile and patient survival. Arch Pathol Lab Med 130 (2006) 1819-1824
28. Andreadis C., Gimotty P.A., Wahl P., et al. Members of the glutathione and ABC-transporter families are associated with clinical outcome in patients with diffuse large B-cell lymphoma. Blood 109 (2007) 3409-3416
29. Goss P.E., Shepherd F.A., Scott J.G., et al. Dexamethasone/ifosfamide/cisplatin/etoposide (DICE) as therapy for patients with advanced refractory non-Hodgkin's lymphoma: preliminary report of a phase II study. Ann Oncol 2 Suppl 1 (1991) 43-46
30. Coiffier B.B. Ifosfamide in the treatment of lymphoma. Semin Oncol 23 (1996) 2-7
31. Antman K.H., Montella D., Rosenbaum C., et al. Phase II trial of ifosfamide with mesna in previously treated metastatic sarcoma. Cancer Treat Rep 69 (1985) 499-504
32. Moskowitz C.H., Bertino J.R., Glassman J.R., et al. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J Clin Oncol 17 (1999) 3776-3785
33. Haim N., Ben-Shahar M., Faraggi D., et al. Dexamethasone, etoposide, ifosfamide, and cisplatin as second-line therapy in patients with aggressive non-Hodgkin's lymphoma. Cancer 80 (1997) 1989-1996
34. Kewalramani T., Zelenetz A.D., Nimer S.D., et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 103 (2004) 3684-3688
35. Biagi J.J., Herbert K.E., Smith C., et al. A phase II study of dexamethasone, ifosfamide, cisplatin and etoposide (DICE) as salvage chemotherapy for patients with relapsed and refractory lymphoma. Leukemia Lymphoma 46 (2005) 197-206
36. Kantarjian H., Barlogie B., Plunkett W., et al. High-dose cytosine arabinoside in non-Hodgkin's lymphoma. J Clin Oncol 1 (1983) 689-694
37. Josting A., Sieniawski M., Glossmann J.P., et al. High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study. Ann Oncol 16 (2005) 1359-1365
38. Velasquez W.S., McLaughlin P., Tucker S., et al. ESHAP-an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol 12 (1994) 1169-1176
39. Hänel M., Kröger N., Hoffknecht M.M., et al. ASHAP-an effective salvage therapy for recurrent and refractory malignant lymphomas. Ann Hematol 79 (2000) 304-311
40. Press O.W., Livingston R., Mortimer J., et al. Treatment of relapsed non-Hodgkin's lymphomas with dexamethasone, high-dose cytarabine, and cisplatin before marrow transplantation. J Clin Oncol 9 (1991) 423-431
41. Velasquez W.S., Cabanillas F., Salvador P., et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 71 (1988) 117-122
42. Soussain C., Souleau B., Gabarre J., et al. Intensive chemotherapy with hematopoietic cell transplantation after ESHAP therapy for relapsed or refractory non-Hodgkin's lymphoma. Results of a single-centre study of 65 patients. Leukemia Lymphoma 33 (1999) 543-550
43. Olivieri A., Brunori M., Capelli D., et al. Salvage therapy with an outpatient DHAP schedule followed by PBSC transplantation in 79 lymphoma patients: an intention to mobilize and transplant analysis. Eur J Haematol 72 (2004) 10-17
44. Chau I., Webb A., Cunningham D., et al. An oxaliplatin-based chemotherapy in patients with relapsed or refractory intermediate and high-grade non-Hodgkin's lymphoma. Br J Haematol 115 (2001) 786-792
45. Micallef I.N., Apostolidis J., Rohatiner A.Z., et al. Factors which predict unsuccessful mobilisation of peripheral blood progenitor cells following G-CSF alone in patients with non-Hodgkin's lymphoma. Hematol J 1 (2000) 367-373
46. Seymour J.F., Grigg A.P., Szer J., et al. Cisplatin, fludarabine, and cytarabine: a novel, pharmacologically designed salvage therapy for patients with refractory, histologically aggressive or mantle cell non-Hodgkin's lymphoma. Cancer 94 (2000) 585-593
47. Fosså A., Santoro A., Hiddemann W., et al. Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol 17 (1999) 3786-3792
48. Papageorgiou E.S., Tsirigotis P., Dimopoulos M., et al. Combination chemotherapy with gemcitabine and vinorelbine in the treatment of relapsed or refractory diffuse large B-cell lymphoma: a phase-II trial by the Hellenic Cooperative Oncology Group. Eur J Haematol 75 (2005) 124-129
49. Di Renzo N., Brugiatelli M., Montanini A., et al. Vinorelbine, gemcitabine, procarbazine and prednisone (ViGePP) as salvage therapy in relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL): results of a phase II study conducted by the Gruppo Italiano per lo Studio dei Linfomi. Leukemia Lymphoma 47 (2006) 473-479
50. Crump M., Baetz T., Couban S., et al. Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: a Phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). Cancer 101 (2004) 1835-1842
51. Avilés A., Neri N., Huerta-Guzmán J., et al. Gemcitabine and cisplatin in refractory malignant lymphoma. Oncology 66 (2004) 197-200
52. Ng M., Waters J., Cunningham D., et al. Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma. Br J Cancer 92 (2005) 1352-1357
53. Girouard C., Dufresne J., Imrie K., et al. Salvage chemotherapy with mini-BEAM for relapsed or refractory non-Hodgkin's lymphoma prior to autologous bone marrow transplantation. Ann Oncol 8 (1997) 675-680
54. Weaver C.C.H., Zhen B.B., and Buckner C.C.D. Treatment of patients with malignant lymphoma with Mini-BEAM reduces the yield of CD34+ peripheral blood stem cells. Bone Marrow Transplant 21 (1998) 1169-1170
55. Wilson W.H., Bryant G., Bates S., et al. EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma. J Clin Oncol 11 (1993) 1573-1582
56. Gutierrez M., Chabner B.A., Pearson D., et al. Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH. J Clin Oncol 18 (2000) 3633-3642
57. Ardeshna K.M., Kakouros N., Qian W., et al. Conventional second-line salvage chemotherapy regimens are not warranted in patients with malignant lymphomas who have progressive disease after first-line salvage therapy regimens. Br J Haematol 130 (2005) 363-372
58. Simpson L., Ansell S.M., Colgan J.P., et al. Effectiveness of second line salvage chemotherapy with ifosfamide, carboplatin, and etoposide in patients with relapsed diffuse large B-cell lymphoma not responding to cis-platinum, cytosine arabinoside, and dexamethasone. Leukemia Lymphoma 48 (2007) 1332-1337
59. Chen C.I., Roitman D., Tsang R., et al. "Relative" chemotherapy sensitivity: the impact of number of salvage regimens prior to autologous stem cell transplant for relapsed and refractory aggressive non-Hodgkin's lymphoma. Bone Marrow Transplant 30 (2002) 885-891
60. Bonavida B. Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions. Oncogene 26 (2007) 3629-3636
61. Mounier N., Briere J., Gisselbrecht C., et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 101 (2003) 4279-4284
62. Vellenga E., Notenboom A., van't Veer M., et al. Rituximab (Mabthera) improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL. A prospective randomized HOVON trial. ASH Ann Meet Abstr 108 (2006) 328
63. Morschhauser F., Illidge T., Huglo D., et al. Efficacy and safety of yttrium 90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem cell transplantation. Blood 110 (2007) 54-58
64. Nademanee A., Forman S., Molina A., et al. A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma. Blood 106 (2006) 2896-2902
65. Vose J.M., Bierman P.J., Enke C., et al. Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma. J Clin Oncol 23 (2006) 461-467
66. Gopal A.K., Rajendran J.G., Gooley T.A., et al. A phase II study of myeloablative I-131-anti CD-20 (Tositumomab) radioimmunotherapy and autologous hematopoietic stem cell transplantation (ASCT) for adults >=60 years of age with high-risk relapsed or refractory B-cell lymphoma. ASH Ann Meet Abstr 106 (2005) 487
67. O'Connor O.A., and Hamlin P. New drugs for the treatment of advanced-stage diffuse large cell lymphomas. Semin Hematol 43 (2006) 251-261
68. Pervan M., Calimlim J., Matso D., et al. Active combination therapy of bortezomib (Velcade) and ibritumomab tiuxetan (Zevalin) in an in vivo diffuse large B-cell lymphoma model. ASH Annu Meet Abstr 106 (2005) 2406
69. Hagberg H GC. Randomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B cell lymphoma (DLBCL) followed by high dose therapy and a second randomisation to maintenance treatment with rituximab or not: an update of the CORAL study. Ann Oncol. 2006;17:iv31-iv31.
70. Abramson J.S., and Shipp M.A. Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach. Blood 106 (2005) 1164-1174
71. Robertson M.J., Kahl B.S., Vose J.M., et al. Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 25 (2007) 1741-1746
72. Stopeck A.T., Bellamy W., Unger J., et al. Phase II trials of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin's lymphoma (NHL): Southwest Oncology Group study S0108. Proc Am Soc Clin Oncol 23 (2005) 583s
73. Ganjoo K.N., An C.S., Robertson M.J., et al. Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: safety, biomarker and pharmacokinetic analysis. Leukemia Lymphoma 47 (2006) 998-1005
74. Marks P.A. Discovery and development of SAHA as an anticancer agent. Oncogene 26 (2007) 1351-1356